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Overview
========

In this workshop report, we summarize key issues that exist while performing high-quality flow cytometry. Although these issues are common across flow cytometry applications, we focus on lung-specific concerns. The goal of the report is to improve the rigor and reproducibility of flow cytometry experiments and support potential users of this highly useful technology. The key findings of this workshop are as follows:•Flow cytometers use a combination of fluidics and lasers/detectors to identify surface and intracellular characteristics of single cells to define individual cells in complex tissues or biological fluids.•Performing high-quality flow cytometry experiments requires design based on the specific investigator's research question. On the basis of this question, carefully considered decisions will need to be made on the type of cytometer, the tissue or biologic fluid to be used, the methods of digestion or sample preparation, the design of the flow cytometry panel, flow cytometry performance with attention to items such as compensation and autofluorescence, the analysis of data, and finally the method of reporting flow cytometry data for publication. All of these items require consideration and troubleshooting and can lead to faulty data if not well designed.•Lung tissue digestion methods require optimization for the desired cell type(s) and their viability. Poor tissue digestion either leads to ineffective liberalization of cells from lung tissue or excessive cell death. Furthermore, investigators should also consider the different pulmonary regions (airway, parenchyma, etc.) and if the tissue is normal or diseased, as these factors may alter the digestion.•All flow cytometry samples should include an appropriate viability dye in their panel design. Flow cytometry data analysis then should be restricted to viable cells, as nonviable cells exhibit nonspecific fluorescence ([Figure 1](#fig1){ref-type="fig"}). It is not sufficient to use the light scatter properties of cells (forward scatter \[FSC\] vs. side scatter \[SSC\]) to define cell viability.•When defining individual cell populations, investigators should generally focus on defining cell types using standard markers and then describing how conditions alter surface expression (activation markers, etc.) or the frequency of cell populations. This is important so that the research community has common terminology, enabling better reproducibility of results across laboratories. To support this effort, cell surface markers are provided for standard pulmonary cell populations.•Reports of flow cytometry data for publication should include information on the antibodies (clone, commercial source, conjugated fluorophores, and dilution), the cytometer, and a clear gating strategy for how cells are defined. Placement of flow cytometry data on repositories is encouraged as a part of publication.

![Effect of apoptotic/necrotic cells and cell debris on flow cytometry plots with and without use of a viability dye. The red circle highlights a population of nonviable cells that are identified when a viability dye is not used in the staining conditions. Representative sample of a murine lung tissue digestion. FSC = forward scatter; SSC = side scatter.](rcmb.2019-0191ST_f1){#fig1}

Introduction
============

Increasingly, complex interactions of cells in organ systems are recognized to be drivers of injury and repair programs and crucial to organogenesis and maintenance of homeostasis. Unraveling complex cellular functions and interactions has tremendous potential to improve understanding of disease states and aid in the development of targeted therapeutics. This is particularly important to lung disease, as the lung is a principal immunologic organ, with complex interactions between immune and structural cells. These studies require careful identification and characterization of individual cell populations, principally performed by flow cytometry. Flow cytometry is the vital, mainstream tool for understanding the cellular basis of pathological processes and is the centerpiece of cellular phenotyping.

Cell phenotyping can provide a detailed snapshot of immune and structural function, which can serve to clarify responses in animal models, as a biomarker of disease state/activity, and potentially to direct the implementation of targeted therapeutics. In addition, flow cytometry is increasingly linked to novel -omics approaches (gene expression profiling, epigenomics, proteomics, metabolomics, etc.) and cellular and single-cell biology. However, despite its widespread and ever-increasing use, there are important technical and methodological concerns critical to the performance of high-quality flow cytometry ([@bib1]). These challenges affect the reproducibility and generalizability of the results and can significantly hinder the advancement of research if performed incorrectly. A lack of standardized protocols and tools renders these issues particularly relevant.

Methods
=======

To address these concerns with flow cytometry in the lung, the American Thoracic Society convened a panel of flow cytometry experts. The workshop co-chairs (R.M.T., A.V.M., and C.V.J.) identified international and U.S.-based participants on the basis of their flow cytometry expertise. All participants submitted conflict-of-interest statements before the workshop. The workshop considered the following general topic areas: sample processing, preparation, and cytometers; defining lung-specific reference panels; aspects of working with human lung samples; and methods of data analysis and reporting. The workshop convened on May 18, 2018 at the International Conference of the American Thoracic Society in San Diego, California. Individual workshop participants presented specific topics under the general topic sections. After those presentations, participants discussed the topics, and any key questions and needs were reviewed. Disagreements were resolved with discussion and consensus during the workshop and by subsequent discussions over e-mail. After the workshop, a writing committee was formed to be responsible for drafting the report (R.M.T., A.V.M., C.V.J., Y.-R.Y., B.D.S., and E.F.R.). After the generation of a draft document, all members of the workshop reviewed and revised the document before submission.

Technology and Instrumentation
==============================

Flow cytometers use fluidics to organize cell suspensions into a single-cell stream. Single cells, previously stained with antibodies conjugated to fluorochromes, are then subjected to defined light wavelengths to excite the individual fluorochromes. The emission spectra of these fluorochromes are then measured by specific detectors and converted to digital signals for analysis. The summative responses define individual cells by the unique expression patterns of these specific antibodies. Although in concept this process is relatively straightforward, flow cytometers vary considerably in terms of their configurations.

The components critical to individual cytometers include the laser source, mirrors, filters, and detectors. These features need to be considered both when designing experiments and when comparing results between different sites and instruments. A cytometer's configuration should be reported in all flow cytometry publications---at a minimum, the cytometer make and model ([@bib2]). Low-end analyzers have one to three lasers, whereas high-end analyzers are available with more than five lasers. These lasers can be set up in a colinear or a spatially separate arrangement. Fluorochromes emit light of different wavelengths, which are separated by a series of mirrors into individual wavelengths and then directed to detectors. Importantly, some fluorochromes are excited by different lasers on different instruments, which can change their emission characteristics. Before arriving at detectors, the wavelengths pass through filters to narrow the wavelengths directed to the detector. Long-pass filters allow all light above a specific wavelength to pass, short-pass filters allow light below a specific wavelength to pass, and band-pass filters allow only a specific range of wavelengths to pass. Therefore, it is important to make sure that the emission peak of individual antibody--fluorochrome combinations is appropriate for the associated mirrors and filters. Finally, the wavelengths reach the detectors, which are commonly photomultiplier tubes, although photodiodes are used in some instruments. The voltage can be set for each of the photomultiplier tubes, to maximize fluorescence resolution and dynamic range in the channels used. One generally accepted protocol for performing photomultiplier tube voltage optimization is the stain index voltration method ([@bib3]). Given the complexity of lasers, mirrors, filters, and detectors, it is important to interact with individuals with flow cytometry expertise to ensure cytometry panels are designed appropriately for a given instrument's optical configuration.

Recommendation
--------------

Identify if the configuration of the flow cytometer is optimized for the flow cytometry panel and the experimental design. We recommend consulting with a flow cytometry core staff or an individual with the expertise to assist with panel design to ensure optimal pairing of fluorochromes/antibodies to the instrument's optical configuration.

Other Technology
================

Although traditional flow cytometry remains the main tool for single-cell analysis, several new instruments have been developed that can be useful for the pulmonary research community. These include spectral flow cytometers, imaging cytometers, and mass cytometers.

*Spectral flow cytometers* are similar to traditional flow cytometers, but instead of using only a portion of emitted signal (determined by the optical configuration, i.e., filters and mirrors), they capture the entire emitted spectrum, independent of the markers or fluorescent dyes. Spectral unmixing algorithms, similar to those used in fluorescence microscopy, are then used to deconvolute the data and unmask signal from fluorochromes with overlapping emission spectra. Unlike conventional fluorescence cytometers that dedicate one detector per fluorophore, spectral cytometers can resolve many more fluorophores simultaneously, regardless of the number of detectors.

*Imaging flow cytometry* bridges the gap between fluorescent microscopy (low throughput, low dimensionality, spatial context) and conventional flow cytometry (high throughput, high dimensionality, no spatial context). Current commercially available imaging flow cytometry instruments combine the design of a traditional flow cytometer and a microscope; they can capture images in up to 10 fluorescence channels and at different magnifications. This approach provides information about the cell size and shape and the spatial distribution of its fluorescent signal. Thus, imaging cytometry can provide researchers with high-dimensional data, which come at the expense of slow acquisition, large file size (\>0.5 GB for 10,000 cells), and delayed analysis time, making it less suitable for the analysis of rare events.

*Mass cytometry*, also known as cytometry of time of flight, is an alternative technique that offers increased dimensionality and data yield in single-cell experiments. It uses stable isotopes of rare earth metals instead of fluorochromes. By design, mass cytometry is free from the issues related to spectral overlap/compensation and autofluorescence. In theory, more than 60 channels can be detected simultaneously with minimal signal overlap. However, care should be taken to understand the possibility of metal isotope contaminants in the sample. For example, reports have indicated that the use of medicinal iodine can interfere with mass cytometry analysis in lung samples ([@bib4]). Although the potential gain of information from a well-designed and well-executed mass cytometry experiment is high, this technique requires significant upfront investment in reagents and optimization, as well as reliable infrastructure and experienced personnel. Most importantly, similar to any high-content data, analysis of mass cytometry data requires substantial computational infrastructure and expertise.

Recommendation
--------------

The choice of technology should be appropriate to answer the experimental question and match the researcher's expertise and availability of resources.

Sample Processing and Staining
==============================

Sample processing and staining are a critical component in performing high-quality flow cytometry. The consensus among the workshop group is that poor handling and nonstandardized sample processing is the step most likely to result in poor flow cytometry performance and the one that most frequently leads to the presence of "false-positive" populations. This is because individual methods of tissue digestion and cell processing can alter the expression of cell surface markers and intracellular proteins ([@bib5]--[@bib7]). In addition, debris and apoptotic or necrotic cells accrued as a result of sample processing can lead to spurious cellular signals ([Figure 1](#fig1){ref-type="fig"}). Therefore, before initiating any study, a standardized methodology is required to limit issues with flow cytometry performance and interpretation.

The lung has several unique tissue compartments that can be sampled (airspace, vascular, and tissue/interstitium) and which require different considerations to obtain viable cells. BAL fluid is obtained by instillation and return of fluid through a bronchoscope (humans) or tracheal cannula (rodents). The type of lavage fluid and the method of sampling can vary widely in individual protocols and can affect the cell count ([@bib8]). It is less clear if methodological differences affect the proportion of cell types. Standard methods should be used in human studies, including the type of lavage fluid used, the anatomic location of the lavage, the method of aspiration, and discarding or separately processing the return of the first-instilled aliquot ([@bib9], [@bib10]). After BAL, the lavage fluid should be maintained on ice and processed expeditiously to preserve the viability of the cells.

Lung tissue digestion has fewer standard processes and wide interlaboratory variability. The major concern with tissue digestion is maximizing cell recovery while limiting debris and cellular apoptosis/necrosis. In addition, it is clear that digestion protocols need to be tailored to the cell type, as some protocols favor structural cells over immune cells and vice versa. For example, digestion methods have been designed specifically for the isolation of epithelial cells ([@bib7], [@bib11]), whereas others have designed methods for myeloid cells ([@bib12], [@bib13]). Some labs use purely mechanical disaggregation methodologies without any enzymes to release viable hematopoietic cell types ([@bib14]). Another consideration is the route of tissue digestion mixture administration, which can affect the recovery of specific cell types ([@bib7]). In addition, some cells are more sensitive to digestion enzymes than others, and some digestion enzymes can cleave surface markers, thus preventing detection of the cells of interest ([@bib6], [@bib7], [@bib15]). Finally, digestion protocols may require further optimization, depending on the nature of the disease and tissue injury. Therefore, before initiation of experiments, consideration and testing of the digestion protocol are crucial to the ultimate quality and reproducibility of flow cytometry experiments.

A specific lung tissue consideration is the tissue location of immune and structural cells. As the lung is highly vascularized, immune cells can be located within the vasculature. Investigators have traditionally used tissue perfusion to remove intravascular immune cells, including heparin administration before this perfusion ([@bib16]). However, detailed studies demonstrate that intravascular immune cells remain despite perfusion ([@bib17]). To address this concern, Desch and colleagues designed a protocol for intravascular administration of fluorescent dyes to segregate intravascular from intraparenchymal immune cells ([@bib18]). This technique may be difficult to perform or not required in all experimental settings but should be considered in settings where careful compartment separation is required. An additional compartment consideration is that individual immune and structural cell populations will vary depending on the type of tissue. For example, tissue from central airways will increase the yield of airway epithelial cells and dendritic cells, whereas distal lung tissue will be enriched for alveolar epithelial cells and alveolar macrophages. This must be considered, particularly when attempting to quantify specific immune or structural cell populations.

Sample preservation is a variable in the performance of flow cytometry. There is limited consensus on this issue, particularly in the lung. Cryopreservation has been used with success in peripheral blood immune cells ([@bib19]) but has not been explicitly studied in BAL cells or lung tissue. It is typically recommended to perform flow cytometry on fresh tissue or BAL cells. However, some investigators have fixed cells and then stained them ([@bib20]). In these experiments, the cells were stained with a fixation-resistant viability dye before fixation. The samples then can be maintained for 2 to 3 weeks before performing staining. Alternatively, a design that was effective in a multicenter trial was to stain cells at clinical sites, fix them before shipping, and analyze them on a single flow cytometer ([@bib21]). An initial consideration is that fixatives can degrade some organic and tandem dyes. Therefore, the recommendation is to either have short periods of fixation where the fixative is removed before staining or to account for the use of fixatives when these fluorochromes are used in panel design. Again, it is important to test these conditions between fresh and cryopreserved or fixed samples to confirm that preservation does not affect staining conditions.

Once cells are in a single-cell suspension, the next consideration is the panel design. This choice should be considered with care and in consultation with institutional expertise. To assist with design, the following section (C[onsensus]{.smallcaps} C[ellular]{.smallcaps} M[arkers]{.smallcaps}) suggests cell surface markers to define individual cell populations. Beyond the decision of individual cell-surface markers, other considerations are required. These include the antibody clone (which can affect staining characteristics), fluorochrome/antibody combination, and capabilities of the cytometer (reviewed in Reference [@bib3]). Panels should be tested and adjusted before performance of experiments to ensure they clearly define the cells and markers of interest. All panels should include a viability dye, particularly when using digested tissues. The use of light-scattering properties (FSC vs. SCC) as a sole method to assess cell viability is not sufficient and is associated with spurious flow cytometry results. In situations where excessive debris accumulation cannot be mitigated, a fluorescent DNA-binding dye compatible with the fluorescence panel design can be used on fixed samples to differentiate between cells and nonnucleated debris ([@bib22], [@bib23]).

During staining, antibodies should be used in a master mix cocktail to ensure that variations in staining do not result from differences in antibody concentrations between samples. Such antibody cocktails are stable for weeks and can reduce variability during the longitudinal studies. To this point, some commercial vendors offer lyophilized premade antibody cocktails. Preference should be made for use of monoclonal antibodies that are directly conjugated, which reduces the number of steps involved in staining and increases staining specificity. Particularly with phagocytic cells, Fc receptors should be blocked unless required for a specific cellular signal ([@bib24], [@bib25]). To reduce nonspecific staining, normal rat and mouse serum (in rodent flow cytometry) or normal human serum (in human flow cytometry) should be used in staining conditions. The majority of protocols perform incubation with blocking mixtures (typically Fc receptor block and normal serum) for a period before staining ([@bib16], [@bib26]). Staining should then occur in the presence of the blocking mixture. Furthermore, use of BSA in the staining buffer may prevent nonspecific binding of antibodies due to non-Fc receptor interactions. Antibody concentration should be titrated to work with a set number of cells to prevent over/under staining. After staining, typically at 4°C, washing steps should be performed to remove unbound antibodies. These conditions are important to limit the amount of nonspecific staining.

Recommendation
--------------

Sample processing and staining are critical components of performing reproducible, high-quality flow cytometry. Defining the samples collected, the methods of collection, the tissue processing/digestion, and cryopreservation/fixation needs to be carefully considered and tested. In addition, the conditions of staining need to include appropriate steps to limit nonspecific staining. Failure to do this will lead to spurious staining and poor ability to accurately and reproducibly define cell populations and activation markers.

Analysis and Data Presentation
==============================

Compensation and Gating
-----------------------

Proper compensation and gating are necessary to correctly visualize and interpret flow cytometry data ([@bib27]). New users often perceive compensation as an overly complicated and mysterious procedure, leading them to avoid designing and setting up multicolor experiments in lieu of simple three- or four-color panels. Some experienced users who were trained during the time when modern reagents and algorithms for setting up compensation were lacking may recommend or even insist on using manual compensation. However, in reality, compensation is a simple and logical procedure, and a variety of detailed step-by-step guides are available ([@bib28], [@bib29]); for new and less-experienced investigators it produces better and more reproducible results. Most popular software packages include tools for calculating and applying automated compensation. Thus, users should avoid manual (i.e., nonautomated) compensation, as it is not nearly as accurate as automated compensation. Generally, the compensation matrix depends on a combination of fluorochromes used for staining, rather than on the cell type (*see* section below on autofluorescence).

To define truly positive populations in multicolor experiments, use of fluorescence-minus-one controls, where a sample is stained with all antibodies in a panel except for one, is highly recommended ([@bib29]), although it may be difficult to implement when sample size is limited. An optimized panel containing fluorescence-minus-one controls is particularly important for flow sorting experiments to increase cell purity in a sorted population. Polystyrene antibody capture beads or amine reactive beads can be used to set up reliable compensation controls for fluorochrome-conjugated antibodies and amino-reactive fixable live-dead dyes, correspondingly. FSC (cell size) and SSC (cell granularity) can provide valuable information and assist identification of the cell type of interest (for example, high SSC of granulocytes or alveolar epithelial type II cells). However, these parameters should be used only in conjunction with specific cell markers and not on their own.

Autofluorescence
----------------

All cell types inherently possess autofluorescence due to differing amounts of natural fluorochromes, including nicotinamide adenine dinucleotide phosphate (NAD(P)H), flavins, porphyrin, lipofuscin, and others ([@bib30]). Each of these endogenous fluorophores has distinct excitation and emission characteristics. However, autofluorescence is more pronounced in some cell types. In the lung, alveolar type II cells and alveolar macrophages---cells producing and metabolizing surfactants, respectively---have the highest autofluorescence ([@bib31]). Various factors, such as smoking or environmental exposures, can increase cellular autofluorescence. Generally, autofluorescence is greatest in the violet and green wavelengths and less, though still present, in the red and far-red wavelengths ([@bib30], [@bib32]). Proper panel design and fluorochrome assignment can mitigate autofluorescence-related issues, or autofluorescence can be used to assist with cellular separation. It is important to recognize autofluorescence and distinguish it from undercompensated samples ([@bib33]).

High-Content and Automated Data Analysis
----------------------------------------

Historically, analysis of flow cytometry data was performed by setting user-defined thresholds (gates), typically on two-dimensional plots. In the case of the complex panels, each gate can be further subsampled and reassessed using a different set of parameters, a practice known as sequential gating. Although this approach performs well for simple assays with well-defined markers, the increased number of markers that can be detected in cytometric assays necessitated the introduction of novel tools for analysis. Various dimensionality reduction, visualization, and clustering techniques have been adopted for identification of the specific cellular populations of flow cytometry data, including self-organizing maps, t-distributed stochastic neighbor embedding (tSNE), uniform manifold approximation and projection (UMAP), and Phenograph ([@bib34]--[@bib40]).

Several tools for supervised and unsupervised automated flow cytometry data analysis have been developed and have been shown to outperform expert-driven analysis, making them particularly attractive for analysis of data from large multicenter trials ([@bib41]--[@bib45]). Importantly, these packages support automated data preprocessing (cleaning) and can be organized into multipackage pipelines. Use of these tools and deposition of the raw data into public data repositories (such as FlowRepository) directly address the need for increased rigor, reproducibility, and transparency in flow cytometric studies ([@bib46], [@bib47]). Importantly, almost all of these powerful tools are available at no cost.

Recommendation
--------------

Instrument settings, experimental protocols, gating strategies, and reagents in accordance with appropriate guidelines should always be reported or referenced in publications. Use of open source tools for reproducible analysis and providing access to raw data is highly desirable.

Consensus Cellular Markers
==========================

A significant consideration in the development and utility of flow cytometry is panel design. Panel design should be focused on the individual investigator's experimental question; therefore, there are unlikely to be single comprehensive panels for every study. However, the workshop members agreed that it is important to use common markers and terminology to define cells in the lung and BAL fluid. The importance of such standardization has been expressed in other research communities to harmonize terminology and identification of individual cell types ([@bib48], [@bib49]). Of note, some of these markers exhibit redundancy but are offered to be inclusive. Markers should be used to define the cell population of interest while also using specific markers to exclude other cell populations. Therefore, combinations are required to accurately identify specific cell populations. The workshop group recommended that investigators focus on defining cell types using standard markers and then describing how conditions alter surface expression (activation markers, etc.) or the frequency of cell populations. This is important so that the research community has common terminology, enabling better reproducibility of results across laboratories. To this end, the workshop panel focused on defining some consensus markers of pulmonary cell types. These panels are not meant to be definitive but rather to provide a guide to the pulmonary research community.

Pulmonary Lymphocytes
---------------------

Most markers of lung and alveolar T-cell populations and subpopulations stem from observations in blood, secondary lymphoid organs, and other mucosal tissues ([Table 1](#tbl1){ref-type="table"}). Innate lymphoid cells, mucosal-associated invariant T cells, and natural killer (T) cells are not discussed in this section ([@bib50]--[@bib52]). In mice and humans, lung and alveolar T cells are generally identified by their low level of SSC and expression of a T-cell receptor complex component---CD3ε and specific T-cell receptor subtypes αβ or γδ. CD4^+^ and CD8^+^ subsets, which are nearly mutually exclusive in the lung, can be further defined once the T-cell receptor bearing, low-SSC T-cell population is identified ([@bib7]). A critical CD4^+^ T-cell subtype required for maintenance of immune homeostasis, the Foxp3^+^ regulatory T (Treg) cell, is identified by staining for the Foxp3 transcription factor itself or a transgenic fluorochrome reporter knocked into the *Foxp3* locus. In humans, low expression of CD127 (the IL-7 receptor) and high expression of CD25 (the IL-2 receptor α subunit) on the cell surface identify Treg cells ([@bib10], [@bib53]), although numerous other surface markers have been proposed ([@bib54]). Murine effector T cells are identified by expression of CD44 and low levels of CD62L or CCR7; naive T cells display the opposite pattern ([@bib55], [@bib56]). Human CD4^+^ and CD8^+^ non-Treg T-cell populations include effector-memory (Tem), central memory (Tcm), and naive (Tn), in addition to Tem cells that express CD45RA (TemRA) ([@bib57]--[@bib60]). These four subsets can be defined based on expression of CCR7 (or CD62L) and CD45RA as follows: Tem, CCR7^lo^CD45RA^lo^; Tcm, CCR7^hi^CD45RA^lo^; Tn, CCR7^hi^CD45RA^hi^; and TemRA, CCR7^lo^CD45RA^hi^. T-helper subtypes are generally defined based on intracellular staining for canonical transcription factors and cytokines after *ex vivo* stimulation (e.g., T-box transcription factor 21 and IFN-γ for T-helper cell type 1 \[Th1\], Gata3 and IL-4 for Th2, retinoic acid--related orphan receptor γT and IL-17A for Th17, etc.). In addition, tissue-resident memory T cells (Trm) appear in the lung after complex signaling interactions ([@bib61]). CD11a^+^CD69^+^ status identifies CD4^+^ Trm cells, and CD103^+^CD69^+^ status identifies CD8^+^ Trm cells ([@bib62]--[@bib64]). Finally, other surface markers often used in T cell panels, particularly for human samples, include human leukocyte antigen--DR isotype (HLA-DR) and CD38 (activation) and CD27 and CD45RO (naive/memory) ([@bib65]).

###### 

Lymphocytes

  Population                                                                    Murine Markers                                                                    Human Markers                                        References
  --------------------------------------- ------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------------
  CD4^+^ T cell                                                   Low SSC, CD3ε^+^ or TCRαβ or γδ^+^, CD4^+^                                                           ---                                                  
  CD8^+^ T cell                                                   Low SSC, CD3ε^+^ or TCRαβ or γδ^+^, CD8^+^                                                           ---                                                  
  CD4^+^ Treg cell                                    CD4^+^ T cell expressing *Foxp3*-transgenic fluorochrome, CD25^hi^               CD4^+^ T cell, CD127^lo^, CD25^hi^; intra-nuclear staining for FOXP3   [@bib10], [@bib53], [@bib54]
  Effector T cell                                            CD4^+^ or CD8^+^ T cell, CD62L^lo^CD44^hi^, CD69^hi^                                                  *See* below                                     [@bib55], [@bib56]
  Naive T cell                                               CD4^+^ or CD8^+^ T cell, CD62L^hi^CD44^lo^, CD69^lo^                                  CD4^+^ or CD8^+^ T cell, CCR7^hi^CD45RA^hi^                     [@bib55]--[@bib60]
  Effector-memory T cell                                                              ---                                                                       CCR7^lo^CD45RA^lo^                                          
  Central-memory T cell                                                               ---                                                                       CCR7^hi^CD45RA^lo^                                          
  T helper subset                          Generally defined by transcription factor and cytokine staining (*see* text for examples)                                   ---                                                  
  CD4^+^ tissue-resident memory T cells                                 CD4^+^ T cell, CD11a^+^CD69^+^                                                                 ---                                         [@bib61]--[@bib64]
  CD8^+^ tissue-resident memory T cells                                 CD8^+^ T cell, CD103^+^CD69^+^                                                                 ---                                                  

*Definition of abbreviations*: SSC = side scatter; Treg = regulatory T.

Pulmonary Myeloid Cells
-----------------------

Myeloid cells are cells that derive from a common myeloid progenitor, specifically a myeloblast. Their origin can be either tissue derived (seeded during embryonic development and locally maintained) or bone marrow derived (derived from circulating intermediates via bone marrow production). In the lung, myeloid compartment cells are a mix of tissue-derived (alveolar macrophages, subsets of interstitial macrophages, and monocytes) and bone marrow--derived (subsets of interstitial macrophages and monocytes, neutrophils, eosinophils, and basophils) cells. This origin definition has been worked out in rodents but has not been directly proven in humans. In the recent time frame, several panels have been developed to define pulmonary myeloid cells in rodents ([@bib16], [@bib26], [@bib66]) and humans ([@bib18], [@bib20], [@bib67]). The consensus of individual markers is summarized in [Table 2](#tbl2){ref-type="table"}.

###### 

Myeloid Cells

  Cell Group                                      Population                                                          Murine Markers                                                                            Human Markers                                                           References
  --------------------------- -------------------------------------------------- ---------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- --------------------------------------------------
  Monocytes                                  Classical monocytes                                  CD11b^+^, CD115^+^, CCR2^+^, F4/80, CD43^lo^, Ly6C^hi^                                                CD64^+^, CD14^hi^, CD16^lo/-^                                [@bib16], [@bib18], [@bib20], [@bib26], [@bib67]
                                            Nonclassical monocytes                             CD11b^+^, CD115^+^, F4/80, CD43^hi^, CX~3~CR1^hi^, Ly6C^lo^                                               CD64^+^, CD14^lo^, CD16^hi^                                      [@bib16], [@bib18], [@bib20], [@bib26]
                                          CD14^+^ CD16^+^ monocytes                                                                                                                                       CD64^+^, CD14^+^, CD16^+^                                                 [@bib18], [@bib20]
  Macrophages                                Alveolar macrophages                         CD11b^−^, CD11c^+^, CD64^+^, CD206^+^, CD169^+^, MerTK^+^, Siglec-F^+^                         CD11b^+^, CD11c^+^, CD64^+^, CD206^+^, CD169^+^, CD14^lo/−^                      [@bib16], [@bib18], [@bib20], [@bib26]
                                           Interstitial macrophages               CD11b^+^, CD11c^lo/+^, CD64^+^, CD206^+^, CD169^+/−^, CX~3~CR1^+^, MerTK^+^, CCR2^+/−^                 CD11b^+^, CD11c^+^, CD64^+^, CD206^+^, CD169^lo^, CD14^hi^                                 [@bib76], [@bib77]
  Monocyte-derived cells       Monocyte-derived macrophages (acute lung injury)                    CD11b^+^, CD64^+^, CX~3~CR1^+^, Ly6C^+/−^, CCR2^+/−^                                                              ---                                                  [@bib16], [@bib75], [@bib78], [@bib79]
  Murine classical DC (cDC)                 CD103^+^ CD11b^−^ cDC                  CD11c^+^, MHCII^+^, MerTK^−^, CD64^−^, CD24^+^, CD26^+^, CD11b^−^, CD103^+^, XCR1^+^                                              ---                                                                 [@bib16]
                                            CD103^−^ CD11b^+^ cDC                 CD11c^+^, MHCII^+^, CD64^−^, MerTK^−^, CD24^+^, CD26^+^, CD301^−^, CD11b^+^, SIRPα^+^                                              ---                                                                     
  Human DC                                       Pulmonary DC                                                              ---                                              CD11c^+^, MHCII^+^, CD64^−^, CD1c^+^, CD141^−^, CD206^−^, CD169^−^, CD14^−^, CD1a^+^                         [@bib20]
                                                 CD1a^hi^ DC                                                               ---                                             CD11c^+^, MHCII^+^, CD64^−^, CD1c^+^, CD141^−^, CD206^+^, CD169^−^, CD14^lo/−^, CD1a^+^                           
                                                 CD1a^lo^ DC                                                               ---                                              CD11c^+^, MHCII^+^, CD64^−^, CD1c^+^, CD141^−^, CD206^+^, CD169^−^, CD14^+^, CD1a^−^                             
  Granulocytes                                   Neutrophils                                                    SSC^hi^, CD24^+^, Ly6G^+^                                                       SSC^hi^, CD24^+^, CD16^+^, CD15^+^, CD66b^hi^                                       [@bib16], [@bib20]
                                                 Eosinophils                                       SSC^hi^, CD24^+^, Siglec-F^lo^, CD11c^−^, F4/80^lo^                                        SSC^hi^, CD24^+^, CD16^−^, CD66b^lo^, Siglec-8^+^                                          [@bib80]
                                                  Basophils                                   SSC^lo^, CD3^−^, CD19^−^, CD49b^+^, FceRI^+^, CD117^−^, IgE^+^                                         SSC^lo^, CD14^−^, HLA-DR, CD123^+^                                                  [@bib81]

*Definition of abbreviations*: DC = dendritic cell; HLA-DR = human leukocyte antigen--DR isotype; MerTK = tyrosine-protein kinase Mer; MHCII = major histocompatibility complex class II; Siglec = sialic acid--binding immunoglobulin-type lectins; SIRPα = signal regulatory protein α; SSC = side scatter; XCR = X-C motif chemokine receptors. "+/−" signify variable expression depending on the timing after acute lung injury.

Pulmonary Structural Cells (Epithelial Cells, Endothelial Cells, and Stromal Cells)
-----------------------------------------------------------------------------------

The development of appropriate markers for nonimmunologic cells is less mature than other pulmonary cell types. The panels rely on a few cell-specific markers for positive selection along with lineage markers used for negative selection. As a reminder, it is important to consider the digestion technique required to successfully liberate structural cells from tissues. These digestion techniques vary significantly for the isolation of different epithelial cell populations ([@bib68]--[@bib70]), fibroblasts ([@bib68]), and endothelial cells ([@bib7]) and can be different than what is used for immune cell--focused protocols. In addition, stromal cell identification leans heavily on the use of lineage labeling with genetic reporter mice (identified by *italics*) in addition to the use of specific fluorescently conjugated antibodies ([@bib71]). These are defined in [Table 3](#tbl3){ref-type="table"}.

###### 

Pulmonary Structural Cells

  Cell Group                        Population                                                               Murine Markers                                                                                              Human Markers                                                    References
  ------------------- -------------------------------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------
  Epithelial cells          Epithelial cells (general)                                              EpCAM/CD326^+^, CD45^−^, CD31^−^                                                                            EpCAM/CD326^+^, CD45^−^, CD31^−^                                               
                                   Basal cells                                                         NGFR/CD271^+^, *Krt5*^*+*^                                                                                    NGFR/CD271^+^, ITGA^+^                                                [@bib68]
                                    Club cells                                                             CD24^+^, *Scgb1a1*                                                                                               CD24^+^                                                        [@bib82]
                        Alveolar epithelial (type I) cells                                    RAGE (*Ager*), *Hopx*, T1α (Gp38/Podoplanin)                                                                     RAGE (Ager), T1α (Gp38/Podoplanin)                                     [@bib69], [@bib83]
                       Alveolar epithelial (type II) cells                              CD24^−^, *Sftpc, sca 1*^−^, Integrin B4^−^, lysotracker                                              HT2-280^+^, SPC^+^, CD24^−^, Integrin B4^−^, HLA-DR^+^, Lysotracker^+^                   [@bib84]--[@bib88]
                       Alveolar epithelial progenitor cells                                     *Axin2-Tdt,* EpCAM^+^, CD31^−^, CD45^−^                                                                                 TM4SF1, HT2-280                                                    [@bib89]
                            Bronchial epithelial cells                                       EpCAM/CD326^high,^ CD24^high^, Integrin B4^+^                                                                                    ---                                                          [@bib90]
  Endothelial cells        Endothelial cells (general)                                 CD31^+^, EpCAM^−^, CD45^−^, Thrombomodulin, ICAM-2, *Tie2*                                                      CD31^+^ EpCAM^−^, CD45^−^, Thrombomodulin, ICAM-2                              [@bib91], [@bib92]
  Stromal cells                    Fibroblasts                CD45^−^, CD31^−^, EpCAM^−^ PDGFRα (CD140a), PDGFRβ (CD140b), Sca1, CD90, CD49e (Integrin α5), αSMA, lipidtox   CD45^−^, CD31^−^, EpCAM^−^ PDGFRα (CD140a), PDGFRβ (CD140b), CD90, CD49e (Integrin α5), αSMA, lipidtox   [@bib93]--[@bib96]

*Definition of abbreviations*: αSMA = α--smooth muscle actin; EpCAM = epithelial cellular adhesion molecule; ICAM = intercellular adhesion molecule; ITGA = integrin alpha; NGFR = nerve growth factor receptor; PDGFR = platelet-derived growth factor receptor; RAGE = receptor for advanced glycation endproducts; Sftpc = surfactant protein C.

Recommendation
--------------

Flow cytometry panels should be designed to address specific research questions. However, to improve the impact of observations and the reproducibility of the research across laboratories, flow panels should be designed with consideration of standard cell definitions and markers.

Cell Sorting
============

Cell sorting is an essential tool for studying lung biology and disease. It feeds numerous downstream applications: genotyping and transcriptional profiling, proteomics, and *in vivo* (adoptive transfers), and *in vitro* assays.

Immunomagnetic Cell Sorting
---------------------------

Cells can be labeled with antibodies conjugated to paramagnetic particles and thus can be retained in the presence of a strong magnetic field, while unlabeled cells can be washed away. Unlabeled cells can be incubated with a new set of antibodies, and the procedure can be repeated several times to collect fractions of interest ([@bib72]). Various systems and reagent sets are available on the market. It is important to notice, however, that this procedure rarely achieves 100% purity and is generally used to enrich single-cell suspensions for cell types of interest before fluorescence-activated cell sorting.

Fluorescence-activated Cell Sorting
-----------------------------------

Cell sorters allow both simultaneous identification of cells and the collection of specific populations of interest. Most modern sorters create a stable stream of droplets, where each droplet contains a single cell. High-speed electronics allow modern instruments to precisely track the position of each cell and then, by applying an electric charge to the exact droplet of PBS carrying the target cell, an electric field created by the deflection plates can pull the single droplet into a collection vessel. Depending on the instrument, up to six different populations can be collected at the same time. Although each cell type and experimental question may have a unique setup, several general aspects, listed below, should be considered.

To create a stable stream of droplets, the sheath stream is vibrated at a specific frequency and amplitude by way of a transducer or piezo. The cells, in their sample fluid, are introduced into the carrier sheath fluid, where they are focused for laser interrogation and exit the nozzle distributed to one of the droplets. All this is done under significant shear stress and pressure; therefore, sorted-cell viability can be a concern. A small nozzle size generally operates at high pressure, which results in smaller droplets and allows faster sorts. Large nozzles operate at lower pressures, generate big droplets, and sort at a slower speed. Even though the largest cell types in the lung are much smaller than the smallest nozzle, users must keep in mind that cells are still being subjected to dramatic shearing forces as they travel through the nozzle at the high speed. Thus, the nozzle size should be selected appropriately. Although small cells (for example T and B cells) can be safely sorted at high speed on small nozzles, large or fragile cells, such as alveolar macrophages, alveolar epithelial cells fibroblasts, or endothelial cells, should be sorted using large nozzles.

Collection Media
----------------

Generally, capture media should be isotonic, buffered to maintain neutral pH, and contain some protein (FBS or BSA). However, when sorting for proteomic analysis, cells should be stained, kept, and sorted into protein-free buffers to avoid contamination with ambient proteins. For downstream RNA- or DNA-based assays, rare or fragile cells can be sorted directly into a lysis buffer ([@bib10], [@bib73]). However, because densities of the lysis buffer and sorting solution are different and they do not readily mix, users should remember to pause the sort every 3 to 5 minutes and flick the collection tube, to ensure proper lysis.

Recommendation
--------------

Modern cell sorters are easier to operate than their predecessors, and a relatively experienced user should be able to perform sorts independent from the flow core staff once the cytometer has been properly set up and quality-control steps performed. Users are encouraged to do optimization experiments and be fully in charge of all experimental steps, rather than delegating these tasks to the core facility staff.

Components for Reporting Flow Cytometry Data in Publications
============================================================

To improve the quality and reproducibility of flow cytometry, it is important that specific flow cytometry components are reported in publications. These components were discussed by the workshop group and supported by prior publications ([@bib2], [@bib74]). The M[ethods]{.smallcaps} sections of manuscripts should include all of the aspects required to reproduce an individual experiment. These aspects should include clear methods of tissue digestion, sample processing, and staining conditions. Information should be provided on the flow cytometer, including the machine type and configuration ([@bib2]). Antibody panels should be clearly defined, including the source, clone, fluorophore, and the concentration of the antibody in the staining condition. Examples of cytometer configuration and antibody panels are provided in publications ([@bib16], [@bib20], [@bib26], [@bib75]). Data analysis should include a clear gating strategy used in the experiments. To allow the reader to understand how individual cells are defined, representative individual gates should be displayed in an overview figure. Preference should be made for biexponential display, as this allows for visualization of cells on the axis ([@bib27]). Overlay analysis of cells can also be used to support clear separation of cell types and define how the expression of a specific marker varies across cell types. The method of data analysis needs to be clearly defined, including mean or median fluorescence intensity for the histograms used to define enhanced cell surface expression of an individual marker. Cell frequency should be reported and clearly defined in the text, preferably on the basis of either total cell numbers or, when indicated, as a percentages of total cells or of the parent gate. Finally, to facilitate use of datasets by other investigators and to permit secondary analysis of data, increased use of data repositories for published flow cytometry data should be considered.

Conclusions
===========

Flow cytometry is a powerful tool to define immune and structural cells in complex biologic fluids and tissues. As the immunologic underpinnings of diseases increase, flow cytometry facilitates definition of cellular states to drive diagnosis and treatment of disease. However, generating accurate and reproducible flow cytometry data requires a clear understanding of the instrument, the methods of processing and preservation, staining conditions, and panel design and robust data analysis. We hope the issues and the discussion outlined as a part of this workshop group will assist the pulmonary research community considering the use of flow cytometry in their experimental designs.
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